Progress in finding better therapies for breast cancer treatment is hampered by the lack of opportunity to integrate and rapidly test novel therapeutics in the clinical setting. In order to catalyze the
transition from uniform to tailored care, clinical trials to identify markers and mechanisms of resistance to therapy are critical. A collaboration of physicians, researcher and cooperative groups are conducting one such study, the I-SPY
Trial, a multi-center clinical trial of women undergoing neoadjuvant chemotherapy from breast cancer. In order to assist in the conduct of the trial and the analysis of results, a great deal of attention has been paid to facilitating
collaboration, providing infrastructure for data management, analysis, and communication, and developing a commitment to sharing information and developing data standards.
The NCI Center for Bioinformatics (NCICB) is designing a web-based system to support correlative data analysis and centralized reporting of results.
version 1.5
Latest data updates
- Clinical Data 11/06/08
- Agilent 5/22/07
- cDNA 5/17/07
Additional Information:
